In coronary artery occlusion studies, Droxicainide reduced the progression of hypoperfusion to necrosis and reduced the infarct size in dogs[1].Droxicainide reduces ansa node, atrioventricular excitability and contractility, and increases intractable studies on spontaneous beating atrium, electrical stimulation atrium and isolated papillary muscles in rats[2].